The Cooper Companies
COO
$54.30
-0.82%
The Cooper Companies, Inc. is a global medical device company operating two primary segments: CooperVision, a pure-play contact lens business offering spherical, multifocal, and toric lenses under brands like Biofinity, MyDay, and Clariti, and CooperSurgical, which provides equipment and devices for reproductive care, fertility, and women's health, including the Paragard hormone-free IUD. CooperVision controls roughly one-fourth of the U.S. contact lens market, while CooperSurgical holds approximately 17% of the U.S. IUD market and offers the broadest medical device coverage of the entire IVF cycle. The current investor narrative is dominated by a sharp negative reaction to the company's fiscal Q3 2026 earnings report, released September 9-10, 2026, which showed an EPS beat but a revenue miss attributed to U.S. inventory destocking, sending shares down approximately 16% in after-hours trading. This event has intensified debate around demand durability in the contact lens franchise, competitive pressures, and whether the sell-off represents an oversold value opportunity or a fundamental deterioration in the growth story.…
COO
The Cooper Companies
$54.30
Related headlines
Investment Opinion: Should I buy COO Today?
The synthesized recommendation is Hold. The core thesis is that while the stock is deeply oversold and trades at a discount on forward earnings, the near-term uncertainty around revenue growth and margin recovery is too high to justify a Buy. The analyst consensus rating is 'buy' with an average target of $66.21, implying 16.3% upside, but the recent downgrades and wide target range ($58-$75) indicate low conviction. The risk/reward is balanced but not compelling enough for a Buy until there are signs of stabilization.
Supporting evidence includes the forward PE of 12.12x, which is well below the trailing PE of 37.19x and historical multiples, suggesting the market expects a strong earnings recovery. Revenue growth has decelerated to 0.56% in Q3 2026, but the company still generates $678 million in TTM free cash flow and has a conservative debt-to-equity ratio of 0.338. The gross margin of 62.36% remains healthy, though it has compressed. The implied upside to the average analyst target is 16.3%, and the stock is trading at a price-to-book of 1.70x, which is low for a healthcare company with market leadership. However, the EV-to-EBITDA of 15.81x is above the sector median, and ROE of 4.55% is weak.
The biggest risks are a prolonged destocking cycle, further margin erosion, and estimate cuts. The Hold rating would upgrade to Buy if revenue growth reaccelerates above 5% and gross margin stabilizes above 65%, or if the stock drops below $51 (the 52-week low) with improving fundamentals. It would downgrade to Sell if revenue growth turns negative or if gross margin falls below 60%. Relative to its history and peers, the stock appears undervalued on forward earnings but fairly valued on current metrics; the market is pricing in a recovery that has yet to materialize.
Sign up to view all
COO 12-Month Price Forecast
The forward-looking view is neutral with medium confidence. The stock is deeply oversold and trades at a discount on forward earnings, but the near-term uncertainty around revenue growth and margin recovery is high. The base case (55% probability) assumes a gradual recovery to $60-$66, while the bull case (25%) and bear case (20%) are less likely. The key factors are the resolution of destocking, margin stabilization, and analyst estimate revisions. I would upgrade to bullish if revenue growth reaccelerates above 5% and gross margin stabilizes above 65%, and downgrade to bearish if revenue growth turns negative or gross margin falls below 60%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cooper Companies's 12-month outlook, with a consensus price target around $65.80 and implied upside of +21.2% versus the current price.
Average Target
$65.80
0 analysts
Implied Upside
+21.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$58 - $75
Analyst target range
The stock is covered by 14 analysts, with a consensus recommendation of "buy" (mean rating of 2.5 on a scale where 1 is strong buy and 5 is strong sell), though the distribution reveals significant caution: the most recent institutional ratings show a clear skew toward neutral/hold ratings, with B of A Securities downgrading from Buy to Neutral on September 10, 2026, Baird downgrading from Outperform to Neutral on the same date, and William Blair downgrading from Outperform to Market Perform. The average target price of $66.21 implies 16.3% upside from the current price of $56.91, which appears modest given the stock's recent collapse and suggests analysts are not yet pricing in a sharp recovery. The consensus leans cautiously bullish, but the wave of downgrades following the Q3 earnings miss indicates that sentiment is deteriorating and the "buy" rating may be stale.
The target price range spans from a low of $58.00 to a high of $75.00, a spread of $17.00 or approximately 29% of the average target, which signals meaningful uncertainty about the company's near-term trajectory. The high target of $75.00 implies roughly 31.8% upside and likely assumes that the destocking headwind is transitory, that revenue growth reaccelerates to the 6-8% range, and that margins recover toward the 65%+ gross margin levels seen in prior quarters. The low target of $58.00 implies just 1.9% upside and likely prices in a scenario where destocking persists, competitive pressures intensify, and the company's earnings power remains structurally impaired. The estimated EPS average of $6.51 for the forward year is notably above the trailing quarterly run-rate, and the tight range of EPS estimates ($6.43 to $6.59) suggests analysts have high confidence in their forecasts, which may be misplaced given the recent volatility. The wide target spread, combined with the recent downgrades and the stock's 36.8% drawdown, indicates that conviction is low and that further estimate revisions are likely as the company navigates its demand challenges.
Drowning in data?
Find the real signal!
Bulls vs Bears: COO Investment Factors
The bear case currently has stronger evidence due to the sharp revenue deceleration, margin compression, and wave of analyst downgrades. The bull case rests on the forward PE of 12.12x and analyst targets implying upside, but these are based on estimates that may prove too optimistic given the Q3 miss. The most important tension is whether the U.S. inventory destocking is a temporary channel correction or a sign of weakening end-market demand; if it's temporary, the stock is deeply oversold, but if it's structural, the forward estimates are at risk. The stock's low beta and strong balance sheet provide some downside protection, but the lack of a near-term catalyst and deteriorating sentiment suggest caution until revenue growth stabilizes.
Bullish
- Deep Value on Forward Earnings: The forward PE of 12.12x is dramatically below the trailing PE of 37.19x and the historical PE range of 44-57x seen in 2023-2024. This implies the market is pricing in a massive earnings recovery, with estimated EPS of $6.51 for the forward year versus the trailing EPS of $0.0268. If the company merely meets these estimates, the stock is trading at a significant discount to its own history.
- Analyst Consensus Sees Upside: Despite recent downgrades, the consensus recommendation remains 'buy' with an average target price of $66.21, implying 16.3% upside from the current price of $56.91. The high target of $75.00 suggests 31.8% upside if the destocking headwind proves transitory. Fourteen analysts cover the stock, and the low target of $58.00 still represents a 1.9% gain.
- Strong Balance Sheet and Cash Flow: The debt-to-equity ratio of 0.338 is conservative, and the current ratio of 1.89 indicates ample liquidity. Free cash flow of $678 million TTM provides a 4.85% FCF yield, and the company generated $273 million in FCF in Q3 2026 alone. This financial flexibility supports continued investment and potential share repurchases.
- Market Leadership in Contact Lenses: CooperVision controls roughly one-fourth of the U.S. contact lens market, and CooperSurgical holds 17% of the U.S. IUD market with the only hormone-free IUD (Paragard). This entrenched position provides a durable competitive moat and pricing power, especially in specialty lenses like toric and multifocal.
Bearish
- Revenue Growth Collapsed to Near Zero: Q3 2026 revenue grew just 0.56% YoY to $1.066 billion, a sharp deceleration from 6.2% in Q1 and 7.9% in Q2. The U.S. inventory destocking headwind may persist, and there is no evidence yet that end-market demand is reaccelerating. This raises concerns about the durability of the growth story.
- Margin Compression and Earnings Volatility: Gross margin fell to 62.36% in Q3 2026 from 67.98% in Q2 and 67.88% in Q1, and was below the 65.26% in the prior-year Q3. The Q2 2026 quarter was outright unprofitable with a net loss of $77.9 million, and the Q3 net income of $432.8 million was inflated by a $231 million tax benefit, making the 40.6% net margin unsustainable.
- Analyst Downgrades and Stale Buy Rating: Following the Q3 miss, B of A Securities, Baird, and William Blair all downgraded the stock to Neutral or Market Perform on September 10, 2026. The consensus 'buy' rating may be stale, and the average target of $66.21 could see further cuts as analysts revise estimates downward.
- Severe Relative Underperformance: The stock has lagged SPY by 18.98 percentage points over the past month and 32.67 percentage points over the past year, one of the worst relative performances in large-cap healthcare. The 29.84% YTD decline and 23.30% three-month decline indicate a fundamental repricing, not just a technical pullback.
COO Technical Analysis
Cooper Companies is entrenched in a pronounced downtrend, with the current price of $56.91 sitting just 11.6% above its 52-week low of $51.01 and a staggering 36.6% below its 52-week high of $89.83. The 1-year price change of -17.66% masks a far more severe recent deterioration, as the stock has lost 29.84% year-to-date and 23.30% over the past three months. Trading at only 15.2% of its 52-week range (where 0% equals the low and 100% equals the high), the stock is deeply in oversold territory, but the velocity of the decline suggests caution rather than an immediate contrarian buy signal. The 36.82% maximum drawdown underscores the severity of the sell-off, and with the stock hovering near multi-year lows, the burden of proof is on bulls to demonstrate a durable bottom.
Short-term momentum is decisively negative and accelerating to the downside, with a 1-month decline of 18.39% and a 3-month decline of 23.30%, both worse than the 1-year decline of 17.66%, indicating that selling pressure has intensified rather than abated. The most dramatic move occurred in early September 2026, when the stock gapped down from $67.69 on September 8 to $54.17 on September 10, a single-session collapse of roughly 20% triggered by the Q3 revenue miss and destocking disclosure. This divergence between the longer-term trend and the acute recent breakdown signals a fundamental repricing rather than a mere technical pullback, and the absence of any meaningful bounce since then (the stock has drifted between $53.27 and $57.41 for nearly a month) suggests the market is still searching for a floor. Relative strength metrics confirm the underperformance: the stock has lagged SPY by 18.98 percentage points over the past month and 32.67 percentage points over the past year, one of the worst relative performances in large-cap healthcare.
Key technical support is anchored at the 52-week low of $51.01, which, if breached, could open the door to a deeper sell-off given the lack of established support levels below that threshold. Resistance is formidable, with the 52-week high at $89.83 representing a 57.8% premium to the current price, and intermediate resistance likely forming around the $60-$62 zone where the stock consolidated in May 2026 before its June rally. The stock's beta of 0.818 indicates it is roughly 18% less volatile than the broader market, which is somewhat reassuring for risk management but also means the stock lacks the high-beta torque that could engineer a rapid recovery. With a short ratio of 2.96, short sellers are not aggressively positioned, suggesting the decline is driven by long-only selling rather than a crowded short thesis, which could mean the selling pressure is more structural than tactical.
Beta
0.82
0.82x market volatility
Max Drawdown
-36.8%
Largest decline past year
52-Week Range
$51-$90
Price range past year
Annual Return
-22.7%
Cumulative gain past year
| Period | COO Return | S&P 500 |
|---|---|---|
| 1m | -19.8% | +1.0% |
| 3m | -23.2% | +2.5% |
| 6m | -23.7% | +13.9% |
| 1y | -22.7% | +15.0% |
| ytd | -33.1% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COO Fundamental Analysis
Revenue growth has decelerated to a near-standstill, with fiscal Q3 2026 (quarter ended July 31, 2026) revenue of $1.066 billion representing just 0.56% year-over-year growth versus $1.060 billion in the prior-year quarter. The multi-quarter trend reveals a troubling pattern: Q1 2026 revenue of $1.024 billion grew 6.2% YoY from $964.7 million, Q2 2026 revenue of $1.082 billion grew 7.9% YoY from $1.002 billion, but Q3 2026 growth collapsed to 0.56%, a sharp deceleration that management attributed to U.S. inventory destocking. Segment data shows CooperVision generated $717 million and CooperSurgical $349.2 million in the most recent period, with the contact lens franchise (roughly 67% of revenue) likely bearing the brunt of the destocking headwind. The growth trajectory has clearly inflected downward, and the investment case now hinges on whether this is a temporary channel inventory correction or a signal of weakening end-market demand.
Profitability presents a mixed picture with significant quarterly volatility. Q3 2026 net income was $432.8 million, but this figure was inflated by a $231 million income tax benefit (negative tax expense), producing an unsustainable net margin of 40.6%; excluding this benefit, pre-tax income was $201.8 million on $1.066 billion in revenue, implying a more normalized net margin closer to 12-13%. Gross margin in Q3 2026 was 62.36%, down from 67.98% in Q2 2026 and 67.88% in Q1 2026, and below the 65.26% recorded in the prior-year Q3, indicating margin compression that is likely tied to product mix and manufacturing underabsorption. The Q2 2026 quarter was outright unprofitable, with a net loss of $77.9 million and negative operating income of $31 million, reflecting a gross margin of 67.98% that was overwhelmed by $766.4 million in operating expenses. The trailing twelve-month picture is similarly challenged, with a net margin of just 9.16% and an operating margin of 16.69%, both below the company's historical norms and suggesting that cost discipline is deteriorating alongside revenue growth.
Balance sheet metrics are relatively healthy but cash flow quality is a concern. The debt-to-equity ratio of 0.338 is conservative for a medical device company, and the current ratio of 1.89 indicates adequate short-term liquidity. However, free cash flow of $678 million on a trailing twelve-month basis represents a FCF yield of approximately 4.85% (against a $13.98 billion market cap), which is modest for a company trading at a premium valuation. Return on equity of just 4.55% and return on assets of 2.74% are well below what investors would expect from a high-quality medical device franchise, reflecting the earnings volatility and the dilutive impact of the Q2 loss. The cash flow statement reveals that Q3 2026 operating cash flow was $341.7 million against capital expenditures of $68.7 million, generating $273 million in free cash flow, but the company also repurchased $249.5 million in stock during the quarter, leaving limited room for debt reduction or strategic investments.
Quarterly Revenue
$1.1B
2026-07
Revenue YoY Growth
+0.6%
YoY Comparison
Gross Margin
62.4%
Latest Quarter
Free Cash Flow
$678000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COO Overvalued?
Because Cooper Companies reported positive trailing net income (EPS of $0.0268 on a trailing basis, though this is distorted by the Q3 tax benefit), the PE ratio is the primary metric, but its reliability is compromised by the earnings distortion. The trailing PE of 37.19x is elevated, while the forward PE of 12.12x is dramatically lower, implying the market expects a massive earnings recovery in the coming year. This enormous gap between trailing and forward multiples (a 67% decline) reflects the market's expectation that the Q3 tax benefit will not recur and that normalized earnings power is substantially higher than the trailing figure suggests. However, the forward PE of 12.12x is based on estimated EPS of $6.51, which appears aggressive given the current quarterly run-rate of $2.24 (Q3 2026) and the Q2 loss of $0.40.
Relative to the broader medical instruments and supplies sector, Cooper's valuation presents a mixed picture. The price-to-sales ratio of 3.42x and EV-to-sales of 3.20x are moderate for a medical device company with 60.67% gross margins, but the EV-to-EBITDA of 15.81x is above the sector median of approximately 12-14x, suggesting a premium that may not be justified by the company's current 0.56% revenue growth. The price-to-book ratio of 1.70x is notably low for a healthcare company with Cooper's market position, reflecting the market's skepticism about the sustainability of returns on capital. The PEG ratio of -8.14 is negative and therefore not meaningful, but it underscores the disconnect between the company's earnings trajectory and its valuation multiple.
Historically, Cooper Companies has traded at a significant premium to its current valuation. The historical ratios data shows that as recently as Q1 2025 (January 2025), the stock traded at a PE of 46.4x and a PS ratio of 20.1x, while in Q1 2026 (January 2026), the PE was 30.8x and PS was 15.6x. The current PS ratio of 3.42x is a fraction of the 13-20x range seen over the past several years, and the current PE of 37.2x is below the 44-57x range that prevailed through much of 2023-2024. This compression reflects both the earnings deterioration and the de-rating of the stock, and while it could signal a value opportunity, the historical context suggests the market is pricing in a permanent impairment to the company's growth and profitability profile rather than a temporary setback.
PE
37.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~57x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company's revenue growth has stalled at 0.56% YoY in Q3 2026, and gross margin has compressed to 62.36% from 67.98% in the prior quarter. The Q2 2026 net loss of $77.9 million and negative operating income of $31 million highlight earnings volatility. While the debt-to-equity ratio of 0.338 is manageable, the trailing net margin of 9.16% and operating margin of 16.69% are below historical norms, and the Q3 net income was inflated by a one-time tax benefit, masking underlying weakness. Free cash flow of $678 million TTM is solid, but the company spent $249.5 million on buybacks in Q3, leaving limited room for debt reduction or strategic investments.
Market and competitive risks are elevated. The stock trades at an EV-to-EBITDA of 15.81x, above the sector median of 12-14x, despite near-zero growth, leaving it vulnerable to further multiple compression. The beta of 0.818 indicates lower volatility than the market, but the stock has still suffered a 36.82% max drawdown and 29.84% YTD decline. Competitive pressures in the contact lens market from rivals like Alcon and J&J Vision, and in the IUD market from AbbVie's Liletta, could limit pricing power. Recent news highlights macro headwinds, including rising oil prices and Treasury yields, which pressure growth stock valuations and favor value sectors.
In a worst-case scenario, if destocking persists into fiscal 2027 and revenue growth remains below 2%, the forward EPS estimate of $6.51 could be cut by 20-30%, leading to a further de-rating. The stock could retest its 52-week low of $51.01, representing a 10.4% decline from the current price of $56.91. If the low target of $58.00 is breached and the stock falls to $45, that would be a 21% loss. The max drawdown of 36.82% from the 52-week high of $89.83 shows the potential severity; a similar drawdown from current levels would imply a price near $36, though that is an extreme scenario. Realistically, investors could lose 10-20% from current levels if the bear case materializes.
FAQ
The key risks include: 1) Financial risk: revenue growth has stalled at 0.56% YoY, and gross margin has compressed to 62.36% from 67.98%, with Q2 2026 posting a net loss of $77.9 million. 2) Competitive risk: CooperVision faces intense competition in contact lenses from Alcon and J&J, and CooperSurgical's Paragard IUD competes with AbbVie's Liletta. 3) Macro risk: rising interest rates and oil prices pressure growth stock valuations, and the stock has a beta of 0.818 but still suffered a 36.82% max drawdown. 4) Company-specific risk: the U.S. inventory destocking may persist, leading to further estimate cuts and analyst downgrades. The most severe risk is a prolonged destocking cycle that pushes revenue growth negative.
The 12-month forecast has three scenarios: bull case (25% probability) targets $75-$80, assuming destocking resolves and revenue growth rebounds to 6-8%; base case (55%) targets $60-$66, assuming gradual recovery to 3-4% growth; bear case (20%) targets $51-$58, assuming destocking persists and estimates are cut. The base case is most likely, with the stock trading around the average analyst target of $66.21. The key assumption is that the destocking headwind is temporary and resolves by mid-2027. If it proves structural, the bear case becomes more likely.
COO appears undervalued on forward earnings but fairly valued on current metrics. The forward PE of 12.12x is well below the trailing PE of 37.19x and the historical range of 44-57x, suggesting the market expects a strong earnings recovery. However, the EV-to-EBITDA of 15.81x is above the sector median of 12-14x, and the price-to-sales ratio of 3.42x is moderate. The market is pricing in a recovery that has yet to materialize, so the stock is only undervalued if the forward estimates are achievable. Given the recent revenue miss, there is a risk that estimates are too high, making the stock fairly valued at best.
COO is not a clear buy at current levels due to the high uncertainty around revenue growth and margin recovery. The stock trades at a forward PE of 12.12x, which is attractive, and the average analyst target of $66.21 implies 16.3% upside. However, the recent Q3 revenue miss and 0.56% YoY growth, along with a wave of analyst downgrades, suggest that the near-term risks are elevated. The biggest downside risk is a retest of the 52-week low of $51.01, representing a 10.4% decline. For risk-tolerant investors with a long-term horizon, a small position could be justified, but waiting for signs of revenue stabilization is prudent.
COO is more suitable for long-term investment (minimum 2-3 years) than short-term trading. The stock is in a pronounced downtrend with negative momentum, and there is no clear catalyst for a near-term reversal. The beta of 0.818 indicates lower volatility, but the stock has still lost 29.84% YTD. The company does not pay a dividend, so returns depend entirely on price appreciation. Long-term investors can benefit from the potential earnings recovery and the company's market leadership, but they must be patient and tolerate further downside. Short-term traders should avoid until a bottom is confirmed.
